Latest Breaking News On - Jon kaspar bayard - Page 6 : comparemela.com

F Hoffmann-La Roche Ltd: Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

F Hoffmann-La Roche Ltd: Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNathalie meetzJon kaspar bayardDaniel grotzkyKarl mahlerSabine borngrGerard tobinBruno eschliBirgit masjostLoren kalmLisa tuomiThomas schineckerPatrick barthKarsten kleineRxdx panelRoche group

F Hoffmann-La Roche Ltd: Roche s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)

F. Hoffmann-La Roche Ltd: Roche s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) Evrysdi increased survival and reduced need for permanent ventilation Evrysdi has proven efficacy across adults, children and babies 2 months and older Basel, 15 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support. The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation . Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalisations compared to the natural course of Type 1 SMA. Safety f

United statesNathalie meetzLevi garrawayDaniel grotzkyJon kaspar bayardKarl mahlerSabine borngrBasil darrasGerard tobinBruno eschliBirgit masjostLisa tuomiLoren kalmPatrick barthKarsten kleineToddler development

F Hoffmann-La Roche Ltd: FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

? Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment Basel, 13 April 2020 - Roche

United statesNathalie meetzJon kaspar bayardLevi garrawayDaniel grotzkyKarl mahlerKenneth mendezSabine borngrGerard tobinBruno eschliBirgit masjostLoren kalmLisa tuomiPatrick barthKarsten kleineAllergy foundation of america

F Hoffmann-La Roche Ltd: Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%

F. Hoffmann-La Roche Ltd: Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% Placebo Risk reduction 13 1.2 4 copies/mL) 14 0.4 Individuals without any COVID-19 symptoms who lived in the same household as an individual who tested positive to SARS-CoV-2 within the prior four days . Based on the seronegative modified Full Analysis Set population, which includes all randomized subjects without evidence of current or prior SARS-CoV-2 infection (i.e., a negative RT-qPCR test and a negative antibody test) at randomization. Adverse events (AEs) occurred in 20% (n=265 out of 1,311) of REGEN-COV participants and 29% (n=379 out of 1,306) of placebo participants, and serious AEs occurred in 1% (n=10) of REGEN-COV participants and 1% (n=15) of placebo participants. There were 0 REGEN-COV participants and 4 placebo participants who were either hospitali

United kingdomUnited statesNathalie meetzLevi garrawayDaniel grotzkyJon kaspar bayardKarl mahlerSabine borngrGerard tobinBruno eschliBirgit masjostLisa tuomiActemra roactemraLoren kalmPatrick barthKarsten kleine

F Hoffmann-La Roche Ltd: New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio

(0) EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA) OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs) Data for investigational MS medicine fenebrutinib support its safety profile and high potency Additional presentations on investigational programmes, including Alzheimer s disease and Huntington s disease, help advance scientific understanding of neurological disorders Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually Apr

United statesUnited kingdomNathalie meetzLevi garrawayDaniel grotzkyJon kaspar bayardKarl mahlerSabine borngrGerard tobinBruno eschliBirgit masjostLisa tuomiLoren kalmPatrick barthKarsten kleineMovement disorders